Your browser doesn't support javascript.
loading
Intraoperative cell salvage in revision hip arthroplasty.
Walton, Thomas J; Huntley, Daniel; Whitehouse, Sarah L; Davies, Jennifer; Wilson, Matthew J; Hubble, Matthew J W; Howell, Jonathan R; Kassam, A M.
  • Walton TJ; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Huntley D; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Whitehouse SL; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Davies J; Queensland University of Technology, Brisbane, Australia.
  • Wilson MJ; Blood Transfusion Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Hubble MJW; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Howell JR; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Kassam AM; Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Bone Joint J ; 105-B(10): 1038-1044, 2023 Oct 01.
Article en En | MEDLINE | ID: mdl-37777212
ABSTRACT

Aims:

The aim of this study was to perform a systematic review of the evidence for the use of intraoperative cell salvage in patients undergoing revision hip arthroplasty, and specifically to analyze the available data in order to quantify any associated reduction in the use of allogenic blood transfusion, and the volume which is used.

Methods:

An electronic search of MEDLINE (PubMed), Embase, Scopus, and the Cochrane Library was completed from the date of their inception to 24 February 2022, using a search strategy and protocol created in conjunction with the PRISMA statement. Inclusion criteria were patients aged > 18 years who underwent revision hip arthroplasty when cell salvage was used. Studies in which pre-donated red blood cells were used were excluded. A meta-analysis was also performed using a random effects model with significance set at p = 0.05.

Results:

Of the 283 studies which were identified, 11 were included in the systematic review, and nine in the meta-analysis. There was a significant difference (p < 0.001) in the proportion of patients requiring allogenic transfusion between groups, with an odds ratio of 0.331 (95% confidence interval (CI) 0.165 to 0.663) associated with the use of cell salvage. For a total of 561 patients undergoing revision hip arthroplasty who were treated with cell salvage, 247 (44.0%) required allogenic transfusion compared with 418 of 643 patients (65.0%) who were treated without cell salvage. For those treated with cell salvage, the mean volume of allogenic blood which was required was 1.95 units (390 ml) per patient (0.7 to 4.5 units), compared with 3.25 units (650 ml) per patient (1.2 to 7.0 units) in those treated without cell salvage. The mean difference of -1.91 units (95% CI -4.0 to 0.2) in the meta-analysis was also significant (p = 0.003).

Conclusion:

We found a a significant reduction in the need for allogenic blood transfusion when cell salvage was used in patients undergoing revision hip arthroplasty, supporting its routine use in these patients. Further research is required to determine whether this effect is associated with types of revision arthroplasty of differing complexity.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artroplastia de Reemplazo de Cadera Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artroplastia de Reemplazo de Cadera Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article